Intervention in Individuals at Ultra-High Risk for Psychosis: A Review and Future Directions
Patrick D McGorry, Barnaby Nelson, G Paul Amminger, Andreas Bechdolf, Shona M Francey, Gregor Berger, Anita Riecher-Roessler, Joachim Klosterkoetter, Stephan Ruhrmann, Frauke Schultze-Lutter, Merete Nordentoft, Ian Hickie, Philip McGuire, Michael Berk, Eric YH Chen, Matcheri S Keshavan, Alison R Yung
Journal of Clinical Psychiatry | PHYSICIANS POSTGRADUATE PRESS | Published : 2009
Financial disclosure: Dr McGorry has been a consultant to and has received honoraria from Pfizer, AstraZeneca, Janssen, and Eli Lilly; has received grant/research support from AstraZeneca; and has served on speakers or advisory boards of Pfizer. Dr Bechdolf has served on speakers or advisory boards of Eli Lilly, Sanofi-Aventis, and Janssen-Cilag. Dr Berk has been a consultant to AstraZeneca, Eli Lilly, and Janssen-Cilag; has received grant/research support from the National Health and Medical Resource Council, Stanley Medical Research Institute, and Eli Lilly; has received honoraria from AstraZeneca, Servier, Eli Lilly, and Janssen-Cilag; and has served on speakers or advisory boards of AstraZeneca, Eli Lilly, Lundbeck, Pfizer, and Wyeth. Drs Nelson, Amminger, Francey, Berger, Riecher-Rossler, Klosterkiitter, Ruhrmann, SchultzeLutter, Nordentoft, Hickie, McGuire, Chen, Keshavan, and Yung report no financial or other relationship relevant to the subject of the article.